The DMD community meets the FDA – Part – 2
The DMD community meets the FDA at the AdCom conference. Testimonial, part 2. Indeed, it was tough for me to attend the AdCom Conference. Throughout the day, monuments of data were built and [...]
The Duchenne muscular dystrophy community meets the FDA – Part-1
On April 25, two representatives from the Force traveled to Washington, DC, to attend the AdCom Conference of the Food & Drug Administration (FDA), which focused on the approval of new [...]
New treatments for Duchenne muscular dystrophy: a stalled process
Initial Duchenne muscular dystrophy diagnoses usually come about around age 4 or 5 years, mostly in young boys. Duchenne muscular dystrophy often referred to as “DMD”, is the most severe form of [...]
